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The renal sympathetic nerves have significant contribution to the control of different
aspects of kidney function. Early animal studies of renal denervation in a large number of
different models of hypertension showed that that RDN improved BP control. Recently,
data from prospective cohorts and randomized studies showed that renal denervation
therapy (RDN) is a safe procedure but is associated with only modest reduction of
ambulatory blood pressure (BP) in patients on intensive medical therapy. The main goal
of this article is to review the results of preclinical and clinical studies on the contribution of
the renal sympathetic nervous system to hypertension and the therapeutic applications
of catheter-based renal denervation.
Keywords: resistant hypertension, renal denervation therapy
Introduction
Sympathetic activation participates in the development of the hypertension, by promoting the
initial blood pressure elevation in the early clinical stages of the disease, and maintaining the
blood pressure elevation (Johns et al., 2011). The adrenergic overdrive triggers not only elevations
in blood pressure but contributes over time to end-organ damage and metabolic abnormalities
detected in hypertensive patients.
Four decades ago Muller and Barajas (1972) reported the anatomical basis for a direct action
of the sympathetic nervous system on renal tubular function by showing that norepinephrine-
containing renal sympathetic nerve terminals are in direct contact with the basal membrane of all
renal tubular segments, suggesting that renal sympathetic nerve activity can regulate renal tubular
transport function. Indeed, the efferent and afferent renal nerves convey sensory stimuli between
the sympathetic system and the kidney, thus providing a control system for the regulation of
renal function (DiBona and Kopp, 1997). Under normal conditions, the renal sympathetic nerves
regulate sodium homeostasis and participate in the arterial blood pressure (BP) control. In hyper-
tensives, pathological alterations of this system contribute to abnormalities in sodium reabsorption
and poorly controlled BP.
Despite the success of drug therapy in treating HTN and reducing associated adverse
cardiovascular effects, the percentage of patients achieving adequate BP control worldwide
remains low. According to the National Health and Nutrition Examination Survey (NHANES)
dataset (Egan et al., 2011; Persell, 2011) the prevalence of resistant hypertension (RH) was
8.9% in hypertensives and 12.8% in treated hypertensives. In randomized controlled tri-
als one third of patients did not achieve BP targets despite receiving ≥3 antihyperten-
sive agents (Cushman et al., 2002; Gupta et al., 2011). In a recent report of data from
the Kaiser Permanente health care systems, the incidence of RH was 1.9% within 1.5
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years (Daugherty et al., 2012) and was related to increased
cardiovascular and renal events.
The complex renal sympathetic system recently became of
interest as renal sympathetic denervation treatment (RDN) was
introduced into the treatment of patients with RH. Early uncon-
trolled cohort studies of patients with RH confirmed the safety
of the procedure and reported substantial office BP reduction
(Krum et al., 2009, 2013; Symplicity HTN-2 Investigators, 2010;
Esler et al., 2014). However, evidence derived from the first ran-
domized controlled trial Simplicity HTN-3 (Bhatt et al., 2014),
failed to meet its primary efficacy end point, suggesting that RDN
does not significantly lower office or ambulatory BP compared to
medical therapy. The goal of this article is to review the role of
the sympathetic renal nervous system in hypertension, in light of
the recently reported results of RDN in patients with RH.
Anatomy and Physiology of the Renal
Sympathetic Nerves and Implications in
Blood Pressure Control
The neural pathways for the sympathetic innervation of the kid-
ney originate from the intermediolateral column of the spinal
cord. Preganglionic fibers connect to ganglia along the sympa-
thetic chain, and the splachnic ganglia including the paraverte-
bral aortorenal ganglia (DiBona and Kopp, 1997). Within the
ganglia, the preganglionic fibers connect with postganglionic
neurons that then project to the kidney. Sympathetic outflow to
the kidney is controlled by neural projections from brain nuclei
such as the rostral ventrolateral medulla (RVLM), to intermedio-
lateral column region of the spinal cord. Afferent sensory infor-
mation arising from the renal sympathetic system travels to the
nucleus tractus solitarius (NTS) where the central integration
begins and as a result pathways are activated that track to the
caudal ventrolateral medulla and RVLM.
The sympathetic nerves pass from the aortorenal ganglia and
come in proximity with the renal artery to enter the kidney at the
hilus after which they divide into smaller bundles in parallel with
the divisions of the arterial circulation. As the nerves traverse
deeper into the kidney, they begin to divide further and to form
a network of fibers that penetrate throughout the cortex, jux-
tamedullary regions, and to a lesser extent in the medulla (Fazan
et al., 2002). Each renal nerve bundle contains approximately
900 fibers. The vast majority of postganglionic sympathetic nerve
fibers entering the kidney are unmyelinated with variable diame-
ters (Sato et al., 2006). In human and animal models the maximal
mean number of nerves was observed in the proximal andmiddle
segments of the renal artery, whereas the least average number of
nerves was seen in the distal segment. The circumferential distri-
bution was greatest in the ventral and least in the dorsal regions
(Tellez et al., 2013; Sakakura et al., 2014). In themain renal artery,
distribution of the distance of nerves from the renal arterial
lumen varied considerably, from <1mm to >10mm; however,
the 75th percentile of the distance was 4.28mm. Interestingly,
20% of hypertensive patients have additional small accessory
renal arteries which also have sympathetic nerves (Sakakura et al.,
2014).
The primary neurotransmitter released by the renal sympa-
thetic nerves is norepinephrine. Stimulation of the renal sym-
pathetic nerves increases norepinephrine production that results
in increased sodium reabsorption by the renal tubular epithe-
lial cells, contraction of smooth muscle cells (Esler et al., 2003),
and renin release by the granular cells of the juxtaglomerular
apparatus (Kopp et al., 1980).
Afferent nerve fibers are also found intrarenally in close vicin-
ity to efferent sympathetic nerve fibers mainly projecting from
the renal pelvis to the first neuron in the dorsal root gan-
glion (Stella and Zanchetti, 1991). Afferent nerves are less abun-
dant compared to efferent and their proportion is not different
between the proximal, middle, and distal segments. The periph-
eral axons of afferent renal sensory nerves may release substance
P and calcitonin gene-related peptide as primary sensory neuro-
transmitters (Kopp et al., 2001). They exert an inhibitory effect
on both ipsilateral and contralateral efferent renal sympathetic
nerve activity. Inhibitory renorenal reflexes regulate of arterial
pressure and sodium balance in normotensive healthy individu-
als leading to decreased afferent renal sympathetic nerve activity
(Kopp et al., 2009). In various pathological conditions, activation
of the afferent renal sensory nerves and the inhibitory renorenal
reflexes are impaired. In these conditions, the excitatory renore-
nal reflexes will contribute to increased sodium retention and
arterial pressure (Kopp et al., 2009).
Under normal quiet and unstressed conditions the level of
renal sympathetic nerve activity does not affect renal blood flow.
However, in states of anxiety and tension or in pathophysiological
states, renal sympathetic nerve activity is sufficiently elevated so
as to increase renal vascular resistance and decrease renal blood
flow (Yoshimoto et al., 2004).
The activation of the renal sympathetic fibers has several
effects. Firstly, efferent renal sympathetic activation decreases
renal blood flow and glomerular filtration rate via contraction of
the preglomerular smooth muscle cells. Secondly, it stimulates
the release of norepinephrine from renal sympathetic nerves’
terminals leading to direct activation of the postsynaptic alpha-
1 adrenoceptors located on the renal tubular epithelial cells
and the activation of beta-1 adrenoceptors on juxtaglomerular
granular cells (Pettinger et al., 1985). The activation of beta1-
adrenoreceptors on juxtaglomerular granular cells increases
renin secretion rate, the stimulation of alpha1b-adrenoreceptors
on renal tubular epithelial cells increases renal tubular sodium
reabsorption, and the stimulation of alpha1a-adrenoreceptors on
the renal arterial resistance vessels decreases renal blood flow
(Pettinger et al., 1985; Plato, 2001).
The importance of increased renal sympathetic nerve activ-
ity in the development of hypertension was supported by the
finding that renal denervation in a large number of different
experimental animal models of hypertension either prevented,
delayed the onset, or reduced the magnitude of the hypertension
(Bonjour et al., 1969; Hesse and Johns, 1984; Kompanowska-
Jezierska et al., 2001; Yoshimoto et al., 2004; Schlaich et al., 2009;
Salman et al., 2010). Bonjour et al., showed that renal dener-
vation in anesthetized dogs (Bonjour et al., 1969), increased in
urinary flow rate and sodium excretion while neither renal blood
flow nor glomerular filtration rate changed. They concluded that
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this increased output of water and sodium was due to the with-
drawal of a direct action of the renal sympathetic nerves acting
on renal tubules. Different groups showed that renal denervation
decreases sodium and water reabsorption in all tubular segments
including the proximal tubules, the loop of Henle and the dis-
tal convoluted tubule (Bello-Reuss et al., 1975, 1977). Addition-
ally, renal denervation blunts the ability of the kidney to increase
renin secretion in response to normal renin releasing stimuli
(Johns, 1985).
Also, the activation of the renal afferent nerves contributes
directly to systemic hypertension by modulating central sympa-
thetic nervous system activity and promoting vasopressin and
oxytocin release from the neuro-hypophysis (Echtenkamp and
Dandridge, 1989). Patients early in the course of essential hyper-
tension often have been demonstrated to have increased effer-
ent sympathetic activity to the kidneys (Katholi, 1983). On the
other hand, patients with essential hypertension with chronic
kidney disease have been found to have increased centrally medi-
ated sympathetic activity, possibly mediated by increased afferent
renal sensory nerve activity (Hausberg et al., 2002).
Based on results from animal models of hypertension, den-
ervation of efferent nerves can reduce renin release and sodium
retention, improve renal blood flow, and facilitate blood pres-
sure control (Holmer et al., 1994) while the denervation of affer-
ent sensory nerves could attenuate the kidneys’ contribution to
centrally mediated sympathetic nervous system activity (Katholi
et al., 1983, 1984).
Renal Denervation Therapy for Patients
with Treatment Resistant Hypertension
Surgical renal denervation has been studied in humans for
the treatment of resistant hypertension and shown effective for
reducing sympathetic outflow to the kidneys, and renin release,
without adversely affecting other functions of the kidney such as
glomerular filtration rate (GFR) and RBF. However, these surgi-
cal approaches were frequently complicated by severe orthostatic
hypotension, and urinary incontinence impotence (Smithwick
and Thompson, 1953).
Renal sympathetic denervation treatment (RDT) using a
radiofrequency ablation catheter presents several significant
advantages over surgical approaches targeting the renal sympa-
thetic nerves. It is a localized procedure, it is minimally inva-
sive, it has no systematic side effects, and its procedural and
recovery times are very short. The Symplicity Renal Denervation
System and newer multielectrode catheters comprise of endovas-
cular energy delivery catheters and an automated radiofrequency
generator. Once in place within the renal artery, the tip of the
catheter is placed against the arterial wall in several places where
it delivers radiofrequency energy to the surrounding sympathetic
nerves according to a proprietary, computer-controlled algo-
rithm. Typical procedure starts distally in the renal artery with
the catheter being withdrawn by pulling and rotating the tip, and
it involves at least 4 focal treatments with a distance of ≥5mm
between each site (Krum et al., 2009; Symplicity HTN-2 Inves-
tigators, 2010). Renal sympathetic nerves are more abundant
in the superior area of the arterial ostium. Recent studies have
shown that in the proximal segments of renal artery these nerved
are localized >5mm from the lumen, a distance which may be
beyond the ablation depth of currently used catheters which is
approximately 3–4mm (Tzafriri et al., 2014).
Early Clinical Studies of RDN
The Symplicity HTN-1 study (Krum et al., 2009) assessed safety
of RDN. Short-term repeat angiography and 6-month magnetic
resonance angiography, available for 34 patients, revealed no
residual luminal irregularities at any treatment site. The effec-
tiveness of RDN was confirmed by renal norepinephrine (NE)
spillover. This assay confirmed a significant mean post-treatment
reduction in renal norepinephrine spillover of 47% in 10 ran-
domly selected patients. In this cohort study, RDN lowered office
systolic blood pressure by 27mm Hg at 12 months, and 85% of
the patients responded to therapy with a reduction of systolic
blood pressure exceeding 10mm Hg (Krum et al., 2009). Impor-
tantly, six of the 45 patients who underwent catheter-based renal
denervation had office systolic blood pressure reductions of less
than 10mm Hg and were non-responders.
At 36 months office BP was reduced by an average of
32/14mmHg in 88 patients with complete data with 6 non-
responders only (Krum et al., 2013). Although, striking and
sustained BP reductions were seen, ambulatory blood pressure
monitoring was not used during follow-up and allowed medica-
tion adjustments during this period. After three years of follow-
up of Symplicity HTN-1 there was still no indication that the
number of antihypertensive medications could be reduced by
RDN (Krum et al., 2013).
A recent larger prospective uncontrolled study specifically
examined the BP response to RDN as measured by ambulatory
BPmonitoring (Mahfoud et al., 2013). In 346 subjects who under-
went RDN following the Symplicity HTN-2 protocol were fol-
lowed for up to 12 months, there was a significant reduction in
24-h systolic BP (−12mm Hg) and diastolic BP (−7mm Hg) at
12 months which was much smaller than the reported office SBP
andDBP reduction. Both these studies had important limitations.
Apart from being nonrandomized and uncontrolled, a high rate
of subjects were lost to follow-up. In the study by Mahfoud et al
(Kopp et al., 1980) the significant discrepancy between office BP
and ambulatory BP reduction may have been due to large bias in
office BP measurements.
The Symplicity HTN-2 multicenter, prospective, randomized
trial (Symplicity HTN-2 Investigators, 2010) assessed the safety
and change in office BP in 106 patients with RH. The inclu-
sion criteria were the same with the first proof-of-concept study.
Office BP was reduced by 32/12mm Hg in the renal dener-
vation group, but did not differ from baseline in the control
group. Similar differences in home BP were seen between the
two groups were observed. Also, RDN reduced BP during exer-
cise without compromising chronotropic competence in patients
with resistant hypertension (Ukena et al., 2011). There were no
serious complications related to the device or procedure. The
results of the 3-year follow-up analysis reported a pronounced
sustained office SBP and DBP reduction with approximately 15%
nonresponders and not substantial reduction in mean number
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of medications (Esler et al., 2014). Despite the limited follow-
up time, number of patients and lack of ambulatory BP this
study showed a significant reduction in office BP can be safely
achieved with catheter-based RDN in patients with resistant
hypertension.
Symplicity HTN-3 and Recent Studies (Table 1)
The Symplicity HTN-3 (Bhatt et al., 2014) randomized 535
patients with resistant essential hypertension and an estimated
glomerular filtration rate above 45mL/min/1.73 m2 to undergo
renal denervation with previous treatment or to maintain pre-
vious treatment alone. At 6 months, the decrease in office and
ambulatory systolic BP in the RDN group was a mean of 14.13
and 7mm Hg respectively compared with a fall of 11.74 and
5mm Hg in the control group. Neither of these differences in BP
met the prespecified criteria for statistically significant superior-
ity. Interestingly, the 7mmHg decrease in ambulatory systolic BP
after RDN was similar to reduction in 24-h ambulatory systolic
BP seen in the 12 patients in the Symplicity HTN-1 study (Krum
et al., 2013) but less pronounced compared to the 11mmHg dif-
ference seen in 20 patients from Symplicity HTN-2 (Symplicity
HTN-2 Investigators, 2010). In the pre-specified subgroup anal-
ysis, office SBP was significantly reduced by RDN in the non-
African American patients and those younger than age 60, but
this was not translated into meaningful difference in ambulatory
BP measurements (Bakris et al., 2014).
The major discrepancies between Symplicity HTN-3 and pre-
vious studies may be in part attributed to baseline population
differences and selection bias. Symplicity HTN-3 included more
obese patients, of African-American decent, at higher cardio-
vascular risk, treated with diuretics and aldosterone antagonists
more frequently compared to Symplicity HTN-2. The Symplic-
ity HTN-3 investigators may have been less experienced than the
Symplicity HTN-1 and 2 investigators. Additionally, the selection
of patients only based on elevated office BP in Symplicity HTN-
1 and HTN-2 may have resulted in selection bias due to lack of
standardization and substantial variability of BP affected by the
regression to the mean phenomenon.
A more recent European cohort study of 109 patients with
RH and a prospective uncontrolled trial of a new multielectrode
catheter confirmed the disparities between office and ambula-
tory measurements and showed modest reduction of ambula-
tory BP (Worthley et al., 2013; Persu et al., 2014). In contrast to
the disappointing reports of Symplicity HTN-3 and subsequent
small studies, the recently reported Global SYMPLICITY Reg-
istry (Böhm et al., 2014) of 1000 consecutively enrolled patients
not only confirmed the safety of RDN but also suggested that
RDN lowers office and ambulatory BPs at 6 months. It is also
noteworthy to mention that beyond BP reduction, RDN has
also been shown to be effective in the treatment of other con-
ditions coexisting with resistant hypertension such as impaired
glucose tolerance (Mahfoud et al., 2011; Witkowski et al., 2011),
obstructive sleep apnea severity (Witkowski et al., 2011), and
left ventricular hypertrophy (Brandt et al., 2012). Brandt et al
examined the effect of RDN on diastolic function and LVH in
patients with resistant hypertension. Besides reduction of sys-
tolic and diastolic blood pressure at 1 and 6 months, similar to TA
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FIGURE 1 | Systolic blood pressure change at symplicity HTN-3 study at 6 months according to ablation pattern.
the effect observed in the Symplicity-2 HTN trial, RDN signifi-
cantly reduced LVH and improved E/E′ prime ratio and isovol-
umetric relaxation time as well as systolic LV function (Brandt
et al., 2012). Notably, in 5 non-responders LV mass index was
significantly decreased while in 4 non-responders the diastolic
function was significantly improved, indicating BP-independent
effects of RD on LVH and diastolic dysfunction. More recently,
Mahfoud et al demonstrated a decrease in LV mass index, as
assessed by using cardiac Magnetic Resonce, in both responders
and non-responders undergoing RDN (Mahfoud et al., 2014).
The beneficial effects of RDN on LV mass independently of BP
reduction were confirmed by Doltra et al in 23 patients under-
going RDN who exhibited reduction of LV mass not exclusively
due to a reversion of myocyte hypertrophy but also to reduction
of interstitial myocardial fibrosis (Doltra et al., 2014). It’s pre-
sumed that these beneficial effects are linked to actions of RDN
on renin-angiotensin-aldosterone axis and sympathic nervous
system activity as discussed above.
However, the favorable metabolic effects of RDN were not
confirmed by Symplicity HTN-3, which did not show any sig-
nificant between-group difference in the change in glycated
hemoglobin levels in the RDN group or in the subgroup of
patients with diabetes (Bhatt et al., 2014).
Based on the findings of the first cohorts and randomized
trials a number of concerns arise regarding the utility of RDN
on patients with RH: (i) A limited number of patients with
RH are candidates for the procedure due to presence of sec-
ondary form of HTN, CKD, normal home BP measurement or
unsuitable anatomy. (ii) A significant portion of patients (15–
30%) will have less than 10/5mmHg BP reduction with RDT due
to procedural-related limitations, operator experience and num-
ber of treatment delivered. In a subgroup analysis of Symplicity
HTN-3 higher number of ablations (10–13) and also ablations
in all for quadrants of the arterial wall cross sections (Figure 1)
were associated with significant ambulatory BP reduction com-
pared to the sham control group (Kandzari et al., 2015). (iii) Non-
adherence to antihypertensive regimens affects more than 50% of
patients with difficult to control hypertension (Jung et al., 2013).
In Symplicity-HTN 3, appropriate combination and dosage of
antihypertensive regimens, improved patient compliance and
assessment with home and ambulatory BP led to substantial BP
reduction in the control group which was greater compared to
previous RDN trials. The importance of medication adherence
and structured adjustment of antihypertensive medications was
also shown in the recently published Oslo RDN trial (Fadl Elmula
et al., 2014), which stopped early in view of the dramatic superi-
ority of adjusted drug treatment and witnessedmedication intake
compared to RDN at 6 months of follow-up. (iv) Finally, RDN
may not be suitable for all subgroups of patients regardless of
the degree of sympathetic activity. In SYMPLICITY HTN-3 sub-
group analysis revealed that African American control patients
demonstrated an unusually greater decrease in systolic blood
pressure compared with non-African American controls and a
blunted response to RDN compared to non-African Americans.
The marked reduction in blood pressure in the sham control
group could be related to a change in medical adherence, type
Frontiers in Physiology | www.frontiersin.org 5 March 2015 | Volume 6 | Article 75
Briasoulis and Bakris Renal sympathetic nerves and hypertension
of therapy or degree of sympathetic activation (Kandzari et al.,
2015).
Conclusion
The renal sympathetic nerves have significant contribution to
the control of different aspects of kidney function. Early ani-
mal studies of renal denervation in a large number of dif-
ferent models of hypertension showed that that RDN either
prevented, delayed the onset, or reduced the magnitude of the
hypertension. Additionally, the preclinical and clinical studies
reviewed above, have provided comprehensive insight into the
mechanisms that account for the BP lowering during suppression
of renal sympathetic outflow and propose an alternative approach
to improve BP control in patients with resistant hypertension.
Future randomized trials should be performed in experienced
centers using newer catheters and better designed techniques
in carefully selected compliant patients on appropriate antihy-
pertensive drug combinations in whom all other measures have
failed.
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